Quantcast
Home > Quotes > ARQL
ARQL

ArQule, Inc. Common Stock (ARQL) Quote & Summary Data

$3.69
*  
0.31
7.75%
Get ARQL Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading ARQL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ARQL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 4.02 / $ 3.66
Share Volume
1,090,621
50 Day Avg. Daily Volume
1,222,292
Previous Close
$ 4
52 Week High / Low
$ 7.21 / $ 1.27
Market Cap
402,186,188
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,090,621
50 Day Avg. Daily Volume:
1,222,292

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.16

Trading Range

The current last sale of $3.69 is 190.55% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.02 $ 7.21
 Low: $ 3.66 $ 1.27

Company Description (as filed with the SEC)

We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These product candidates target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of five product candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine.  ... More ...  


Risk Grade

Where does ARQL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.02
Open Date:
Nov. 19, 2018
Close Price:
$ 3.69
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x